The ReSPonD trial - rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Henderson, Emily J ^a   Lord, Stephen R ^b   Close, Jacqueline C T ^b,c   Lawrence, Andrew D ^d   Whone, Alan ^a,e   Ben Shlomo, Yoav ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d CARDIFF UNIVERSITY   (United Kingdom)

^e NORTH BRISTOL NHS TRUST   (United Kingdom)

Author keywords

Accidental Falls; Acetylcholinesterase; Attention; Cognitive; Dual tasking; Freezing of gait; Gait analysis; Intervention; Parkinson's disease; Randomised control trial

Indexed keywords

PLACEBO; RIVASTIGMINE;

ARTICLE; BODY EQUILIBRIUM; COGNITION; CONTROLLED STUDY; DRUG DOSE TITRATION; DRUG MONITORING; DRUG SAFETY; FALL RISK; FALLING; GAIT; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PARALLEL DESIGN; PARKINSON DISEASE; PHASE 2 CLINICAL TRIAL (TOPIC); PHYSICAL PERFORMANCE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSORIMOTOR FUNCTION;

ACCIDENTAL FALLS; CHOLINESTERASE INHIBITORS; COGNITION DISORDERS; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GAIT DISORDERS, NEUROLOGIC; HUMANS; MALE; PARKINSON DISEASE; PHENYLCARBAMATES; QUALITY OF LIFE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 84888791959     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-188     Document Type: Article

References (54)

1. Muslimovic D, Post B, Speelman JD, Schmand B, de Haan RJ. Determinants of disability and quality of life in mild to moderate Parkinson disease. Neurology 2008, 70:2241-2247. 10.1212/01.wnl.0000313835.33830.80, 18519873.
2. Schenkman M, Cutson TM, Zhu CW, Whetten-Goldstein K. A longitudinal evaluation of patients' perceptions of Parkinson's disease. Gerontologist 2002, 42:790-798. 10.1093/geront/42.6.790, 12451160.
3. Genever RW, Downes TW, Medcalf P. Fracture rates in Parkinson's disease compared with age- and gender-matched controls: a retrospective cohort study. Age Ageing 2005, 34:21-24. 10.1093/ageing/afh203, 15591480.
4. Mak MKY, Pang MYC. Fear of falling is independently associated with recurrent falls in patients with Parkinson's disease: a 1-year prospective study. J Neurol 2009, 256:1689-1695. 10.1007/s00415-009-5184-5, 19479166.
5. Hely MA, Morris JGL, Traficante R, Reid WGJ, Sullivan DJO, Williamson PM. The Sydney multicentre study of Parkinson' s disease: progression and mortality at 10 years. J Neurol 1999, 67:300-307.
6. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord 2006, 12:35-41.
7. Wenning GK, Ebersbach G, Verny M, Chaudhuri KR, Jellinger K, McKee A, Poewe W, Litvan I. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord 1999, 14:947-950. 10.1002/1531-8257(199911)14:6<947::AID-MDS1006>3.0.CO;2-O, 10584668.
8. Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson's disease?. J Neurol 2002, 249:419-423. 10.1007/s004150200032, 11967646.
9. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007, 68:384-386. 10.1212/01.wnl.0000247740.47667.03, 17082464.
10. Pickering RM, Grimbergen YAM, Rigney U, Ashburn A, Mazibrada G, Wood B, Gray P, Kerr G, Bloem BR. A meta-analysis of six prospective studies of falling in Parkinson's disease. Mov Disord 2007, 22:1892-1900. 10.1002/mds.21598, 17588236.
11. Hely MA, Reid WGJ, Adena MA, Halliday GM, Morris JGL. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord 2008, 23:837-844. 10.1002/mds.21956, 18307261.
12. Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors. J Neurol 2005, 252:1310-1315. 10.1007/s00415-005-0855-3, 15895303.
13. López IC, Ruiz PJG, Del Pozo SVF, Bernardos VS. Motor complications in Parkinson's disease: ten year follow-up study. Mov Disord 2010, 25:2735-2739. 10.1002/mds.23219, 20931632.
14. Karachi C, Grabli D, Bernard FA, Tande D, Wattiez N, Belaid H, Bardinet E, Prigent A, Nothacker H-P, Hunot S, Hartmann A, Lehericy S, Hirsch EC, Francois C. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J Clin Invest 2010, 120:2745-2754. 10.1172/JCI42642, 2912198, 20628197.
15. Bohnen NI, Muller MLTM, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology 2009, 73(20):1670-1676. 10.1212/WNL.0b013e3181c1ded6, 2788804, 19917989.
16. Rinne JO, Ma SY, Lee MS, Collan Y, Röyttä M. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. Parkinsonism Relat Disord 2008, 14:553-557. 10.1016/j.parkreldis.2008.01.006, 18329941.
17. Lawrence AD, Sahakian BJ. Alzheimer disease, attention, and the cholinergic system. Alzheimer Dis Assoc Disord 1995, 9(2):37-49.
18. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, Mollenhauer B, Adler CH, Marder K, Williams-Gray CH, Aarsland D, Kulisevsky J, Rodriguez-Oroz MC, Burn DJ, Barker RA, Emre M. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov Disord 2012, 27:349-356. 10.1002/mds.24893, 3641655, 22275317.
19. Nakano I, Hirano A. Parkinson's disease: neuron loss in the nucleus basalis without concomitant Alzheimer's disease. Ann Neurol 2004, 15(5):415-418.
20. Jellinger K. The morphological basis of mental dysfunction in Parkinson's disease. J Neurol Sci 2006, 248:167-172. 10.1016/j.jns.2006.05.002, 16797594.
21. Hilker R, Thomas A, Klein J. Dementia in Parkinson disease functional imaging of cholinergic and dopaminergic pathways. Neurology 2005, 65:1716-1722. 10.1212/01.wnl.0000191154.78131.f6, 16344512.
22. Kahneman D. Attention and effort, Volume 88 1973, Englewood Cliffs, NJ: Prentice-Hall.
23. Kelly V, Eusterbrock A, Shumway-Cook A. A review of dual-task walking deficits in people with Parkinson's disease: motor and cognitive contributions, mechanisms, and clinical implications. Park Dis 2012, 2012:918719.
24. Bloem BR, Grimbergen YAM, van Dijk JG, Munneke M. The " posture second" strategy: a review of wrong priorities in Parkinson's disease. J Neurol Sci 2006, 248:196-204. 10.1016/j.jns.2006.05.010, 16806270.
25. Montero-Odasso M. Can cognitive enhancers reduce the risk of falls in people with dementia? An open-label study with controls. J Am Geriatr Soc 2009, 57:359-360. 10.1111/j.1532-5415.2009.02085.x, 19207156.
26. Assal F, Allali G. Galantamine improves gait performance in patients with Alzheimer's disease. J Am Geriatr Soc 2008, 56:946-947. 10.1111/j.1532-5415.2008.01657.x, 18454755.
27. Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010, 75:1263-1269. 10.1212/WNL.0b013e3181f6128c, 3013493, 20810998.
28. Montero-Odasso M, Wells JL, Borrie MJ, Speechley M. Can cognitive enhancers reduce the risk of falls in older people with mild cognitive impairment? A protocol for a randomised controlled double blind trial. BMC Neurol 2009, 9:42. 10.1186/1471-2377-9-42, 3224736, 19674471.
29. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008, 19:385-397. 10.1007/s00198-007-0543-5, 2267485, 18292978.
30. Hippisley-Cox J, Coupland C. Derivation and validation of updated QFracture algorithm to predict risk of osteoporotic fracture in primary care in the United Kingdom: prospective open cohort study. BMJ 2012, 344:e3427. 10.1136/bmj.e3427, 22619194.
31. Rockwood K, Song X, Macknight C, Bergman H, Hogan DB, Mcdowell I, Mitnitski A. A global clinical measure of fitness and frailty in elderly people. Can Med J 2005, 173:489-495.
32. Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, Seeman T, Tracy R, Kop WJ, Burke G, McBurnie MA. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001, 56:M146-M157. 10.1093/gerona/56.3.M146, 11253156.
33. Washburn R, Smith K, Jette A, Janney C. The Physical Activity Scale for the Elderly (PASE): development and evaluation. J Clin Epidemiol 1993, 46:153-162. 10.1016/0895-4356(93)90053-4, 8437031.
34. Schrag A, Selai C. The EQ-5D-a generic quality of life measure-is a useful instrument to measure quality of life in patients with Parkinson's disease. J Neurol 2000, 69:67-73.
35. Chou KL, Amick MM, Brandt J, Camicioli R, Frei K, Gitelman D, Goldman J, Growdon J, Hurtig HI, Levin B, Litvan I, Marsh L, Simuni T, Tröster AI, Uc EY. A recommended scale for cognitive screening in clinical trials of Parkinson's disease. Mov Disord 2010, 25:2501-2507. 10.1002/mds.23362, 2978783, 20878991.
36. Broadbent DE, Cooper PF, FitzGerald P, Parkes KR. The Cognitive Failures Questionnaire (CFQ) and its correlates. Br J Clin Psychol 1982, 21:1-16. 10.1111/j.2044-8260.1982.tb01421.x, 7126941.
37. Brown J, Pengas G, Dawson K. Self administered cognitive screening test (TYM) for detection of Alzheimer's disease: cross sectional study. BMJ 2009, 338:b2030. 10.1136/bmj.b2030, 2694259, 19509424.
38. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB A frontal assessment battery at bedside. Neurology 2000, 55(11):1621-1626. 10.1212/WNL.55.11.1621, 11113214.
39. Meara J, Mitchelmore E, Hobson P. GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing 1999, 28:35-38. 10.1093/ageing/28.1.35, 10203202.
40. Nieuwboer A, Rochester L, Herman T, Vandenberghe W, Emil GE, Thomaes T, Giladi N. Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson's disease and their carers. Gait Posture 2009, 30:459-463. 10.1016/j.gaitpost.2009.07.108, 19660949.
41. Lord S, Ward J, Williams P. Exercise effect on dynamic stability in older women: a randomized controlled trial. Arch Phys Med Rehabil 1996, 77(March):232-236.
42. Lord S, Menz H, Tiedemann A. A physiological profile approach to falls risk assessment and prevention. Phys Ther 2003, 83:237-252.
43. Paul SS, Canning CG, Sherrington C, Lord SR, Close JCT, Fung VSC. Three simple clinical tests to accurately predict falls in people with Parkinson's disease. Mov Disord 2013, 28:655-662. 10.1002/mds.25404, 23450694.
44. Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008, 23:2129-2170. 10.1002/mds.22340, 19025984.
45. Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin SLR. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004, 351:2509-2518. 10.1056/NEJMoa041470, 15590953.
46. Feldman HH, Ferris S, Winblad B, Sfikas N, Mancione L, He Y, Tekin S, Burns A, Cummings J, del Ser T, Inzitari D, Orgogozo J-M, Sauer H, Scheltens P, Scarpini E, Herrmann N, Farlow M, Potkin S, Charles HC, Fox NC, Lane R. Effect of rivastigmine on delay to diagnosis of Alzheimer's disease from mild cognitive impairment: the InDDEx study. Lancet Neurol 2007, 6:501-512. 10.1016/S1474-4422(07)70109-6, 17509485.
47. Hausdorff JM. Gait variability : methods, modeling and meaning. J Neuroeng Rehabil 2005, 2:19. 10.1186/1743-0003-2-19, 1185560, 16033650.
48. Latt MD, Lord SR, Morris JGL, Fung VSC. Clinical and physiological assessments for elucidating falls risk in Parkinson's disease. Mov Disord 2009, 24:1280-1289. 10.1002/mds.22561, 19425059.
49. Dalrymple-Alford JC, MacAskill MR, Nakas CT, Livingston L, Graham C, Crucian GP, Melzer TR, Kirwan J, Keenan R, Wells S, Porter RJ, Watts R, Anderson TJ. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010, 75:1717-1725. 10.1212/WNL.0b013e3181fc29c9, 21060094.
50. Delbaere K, Smith ST, Lord SR. Development and initial validation of the iconographical falls efficacy scale. J Gerontol A Biol Sci Med Sci 2011, 66:674-680.
51. Lamb SE, Jørstad-Stein EC, Hauer K, Becker C. Development of a common outcome data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus. J Am Geriatr Soc 2005, 53:1618-1622. 10.1111/j.1532-5415.2005.53455.x, 16137297.
52. Maki BE. Gait changes in older adults: predictors of falls or indicators of fear. J Am Geriatr Soc 1997, 45:313-320.
53. Hausdorff JM, Balash J, Giladi N. Effects of cognitive challenge on Gait variability in patients with Parkinson's disease. J Geriatr Psychiatry Neurol 2003, 16:53-58.
54. Robertson MC, Campbell AJ, Herbison P. Statistical analysis of efficacy in falls prevention trials. J Gerontol A Biol Sci Med Sci 2005, 60:530-534. 10.1093/gerona/60.4.530, 15933397.